DoW Arthritis Translational Research Award
Defense Health Agency Contracting Activity - DHACA
Program funding
$1,600,000
- Opportunity #
- HT942526ATRPTRA
- Agency
- Defense Health Agency Contracting Activity - DHACA
- ALN (CFDA)
- 12.420
- Status
- posted
- Posted
- May 1, 2026
- Closes
- Oct 22, 2026
- Funding instrument
- Grant
- Category
- Science and Technology and other Research and Development
- Cost sharing required
- No
Who can apply
- •Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Synopsis
Summary: The fiscal year 2026 (FY26) Arthritis Research Program (ATRP) Translational Research Award (TRA) supports high-impact translational research that will accelerate critical findings into clinically relevant solutions. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to Service Members, Veterans, their Families and the American public. Research addressing any and all types of arthritis is encouraged.
Distinctive Features: The FY26 ATRP TRA mechanism is intended to support preclinical or animal research and may not be used for clinical research or clinical trials. Basic research, as defined in Section 3.1.2, is not allowed. A key aspect of this award mechanism is impact. The application should explicitly state how outcomes of the proposed research will significantly advance arthritis research, particularly in accelerating critical findings into clinically relevant solutions.
Preliminary and/or published data, originating from research conducted by the applicant(s) or others, is required.
Contact
JoAnn Martin Grantor · help@eBRAP.org